PAVmed Inc. (NASDAQ:PAVM) Sees Large Increase in Short Interest

PAVmed Inc. (NASDAQ:PAVM) saw a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 293,400 shares, an increase of 19.0% from the August 15th total of 246,600 shares. Currently, 3.2% of the shares of the company are short sold. Based on an average trading volume of 81,900 shares, the short-interest ratio is presently 3.6 days.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets dropped their price target on shares of PAVmed from $22.00 to $21.00 and set a “buy” rating for the company in a research report on Tuesday, September 10th.

PAVmed Price Performance

Shares of NASDAQ PAVM traded down $0.04 during mid-day trading on Tuesday, reaching $1.73. The company’s stock had a trading volume of 87,794 shares, compared to its average volume of 71,154. PAVmed has a 52 week low of $0.60 and a 52 week high of $5.70. The stock has a fifty day moving average of $0.99 and a two-hundred day moving average of $1.47. The firm has a market capitalization of $16.27 million, a PE ratio of -0.19 and a beta of 0.66.

PAVmed (NASDAQ:PAVM) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.84) earnings per share for the quarter. The business had revenue of $0.98 million during the quarter. Analysts anticipate that PAVmed will post -5.88 EPS for the current fiscal year.

PAVmed Company Profile

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.